Symbols / TARA
TARA Chart
About
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 293.12M |
| Enterprise Value | 82.06M | Income | -52.90M | Sales | — |
| Book/sh | 3.43 | Cash/sh | 3.44 | Dividend Yield | — |
| Payout | 0.00% | Employees | 28 | IPO | — |
| P/E | — | Forward P/E | -3.77 | PEG | — |
| P/S | — | P/B | 1.60 | P/C | — |
| EV/EBITDA | -1.38 | EV/Sales | — | Quick Ratio | 13.49 |
| Current Ratio | 13.69 | Debt/Eq | 2.76 | LT Debt/Eq | — |
| EPS (ttm) | -1.39 | EPS next Y | -1.45 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -31.30% |
| ROE | -49.42% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 53.59M |
| Shs Float | 35.81M | Short Float | 5.38% | Short Ratio | 2.43 |
| Short Interest | — | 52W High | 7.82 | 52W Low | 2.77 |
| Beta | 1.39 | Avg Volume | 986.57K | Volume | 6.60M |
| Target Price | $25.50 | Recom | Strong_buy | Prev Close | $7.43 |
| Price | $5.47 | Change | -26.38% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$25.50
Mean price target
2. Current target
$5.47
Latest analyst target
3. DCF / Fair value
$-10.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.47
Low
$23.00
High
$30.00
Mean
$25.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2026-01-07 | init | Piper Sandler | — → Overweight | $24 |
| 2025-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-11-19 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-05-22 | init | Jones Trading | — → Buy | $21 |
| 2025-04-28 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-04-16 | init | Scotiabank | — → Sector Outperform | $12 |
| 2025-03-14 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-03-11 | init | LifeSci Capital | — → Outperform | $22 |
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-12-06 | reit | Guggenheim | Buy → Buy | $20 |
| 2024-12-06 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-08-12 | main | Oppenheimer | Outperform → Outperform | $25 |
| 2024-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-04-22 | main | Oppenheimer | Outperform → Outperform | $30 |
| 2024-04-08 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2023-08-04 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
- Protara Therapeutics stock tumbles on trial data release - Investing.com Mon, 23 Feb 2026 22
- Protara Therapeutics (TARA) Shares Drop 22% After Interim Trial Data - GuruFocus Wed, 25 Feb 2026 05
- Protara falls after trial data for lead asset (TARA:NASDAQ) - Seeking Alpha ue, 24 Feb 2026 19
- Experimental bladder cancer drug TARA-002 hits 68% complete response at 6 months - Stock Titan Mon, 23 Feb 2026 22
- Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits ue, 24 Feb 2026 06
- What's Going On With Protara Therapeutics Stock Tuesday? - Protara Therapeutics (NASDAQ:TARA) - Benzinga ue, 24 Feb 2026 12
- Protara Highlights Strong Phase 2 Data for TARA-002 - TipRanks ue, 24 Feb 2026 14
- Protara Therapeutics Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative hu, 04 Dec 2025 08
- 12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga ue, 24 Feb 2026 17
- Cancer, rare disease therapy developer Protara meets investors - Stock Titan hu, 19 Feb 2026 13
- Protara Therapeutics (TARA) Shares Promising Phase 2 Trial Resul - GuruFocus ue, 24 Feb 2026 00
- SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits ue, 24 Feb 2026 07
- $TARA stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Mon, 22 Sep 2025 07
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 24 Feb 2026 12
- Protara Therapeutics (Nasdaq: TARA) starts $75M stock and pre-funded warrant sale - Stock Titan hu, 04 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 87000 | — | — | Stock Award(Grant) at price 0.00 per share. | SHEFFERMAN JESSE M | Chief Executive Officer | — | 2026-01-16 00:00:00 | D |
| 1 | 30000 | — | — | Stock Award(Grant) at price 0.00 per share. | ZUMMO JACQUELINE | Chief Operating Officer | — | 2026-01-16 00:00:00 | D |
| 2 | 26000 | — | — | Stock Award(Grant) at price 0.00 per share. | CONKLING WILLIAM | Officer | — | 2026-01-16 00:00:00 | D |
| 3 | 9500 | — | — | Stock Award(Grant) at price 0.00 per share. | FRY HANNAH | Officer | — | 2026-01-16 00:00:00 | D |
| 4 | 26000 | — | — | Stock Award(Grant) at price 0.00 per share. | NICACIO LEONARDO VIANA M.D. | Officer | — | 2026-01-16 00:00:00 | D |
| 5 | 28000 | — | — | Stock Award(Grant) at price 0.00 per share. | FABBIO PATRICK | Chief Financial Officer | — | 2026-01-16 00:00:00 | D |
| 6 | 18667 | — | — | Stock Gift at price 0.00 per share. | SHEFFERMAN JESSE M | Chief Executive Officer | — | 2025-06-27 00:00:00 | D |
| 7 | 300000 | — | — | Stock Gift at price 0.00 per share. | SHEFFERMAN JESSE M | Chief Executive Officer | — | 2025-06-24 00:00:00 | D |
| 8 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | CONKLING WILLIAM | Officer | — | 2025-06-02 00:00:00 | D |
| 9 | 20000 | 63800 | — | Purchase at price 3.19 per share. | LEVY RICHARD S | Director | — | 2025-05-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -48.86M | -43.28M | -35.07M | -45.40M |
| TotalUnusualItems | 36.00K | 12.00K | -29.50M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 36.00K | 12.00K | -29.50M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -44.60M | -40.42M | -65.95M | -47.25M |
| ReconciledDepreciation | 332.00K | 341.00K | 248.00K | 117.00K |
| EBITDA | -48.82M | -43.27M | -64.57M | -45.40M |
| EBIT | -49.15M | -43.61M | -64.81M | -45.52M |
| NetInterestIncome | 4.13M | 3.18M | 1.09M | 237.00K |
| InterestExpense | 1.14M | 1.74M | ||
| InterestIncome | 4.13M | 3.18M | 2.23M | 1.97M |
| NormalizedIncome | -44.63M | -40.43M | -36.45M | -47.25M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -44.60M | -40.42M | -65.95M | -47.25M |
| TotalExpenses | 49.15M | 43.61M | 37.55M | 47.49M |
| TotalOperatingIncomeAsReported | -49.15M | -43.61M | -67.06M | -47.49M |
| DilutedAverageShares | 20.59M | 11.33M | 11.26M | 11.23M |
| BasicAverageShares | 20.59M | 11.33M | 11.26M | 11.23M |
| DilutedEPS | -2.17 | -3.57 | -5.86 | -4.21 |
| BasicEPS | -2.17 | -3.57 | -5.86 | -4.21 |
| DilutedNIAvailtoComStockholders | -44.60M | -40.42M | -65.95M | -47.25M |
| NetIncomeCommonStockholders | -44.60M | -40.42M | -65.95M | -47.25M |
| NetIncome | -44.60M | -40.42M | -65.95M | -47.25M |
| NetIncomeIncludingNoncontrollingInterests | -44.60M | -40.42M | -65.95M | -47.25M |
| NetIncomeContinuousOperations | -44.60M | -40.42M | -65.95M | -47.25M |
| PretaxIncome | -44.60M | -40.42M | -65.95M | -47.25M |
| OtherIncomeExpense | 423.00K | 12.00K | -29.50M | |
| OtherNonOperatingIncomeExpenses | 387.00K | |||
| SpecialIncomeCharges | 0.00 | -29.52M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 29.52M | 0.00 | |
| GainOnSaleOfSecurity | 36.00K | 12.00K | 17.00K | |
| NetNonOperatingInterestIncomeExpense | 4.13M | 3.18M | 1.09M | 237.00K |
| InterestExpenseNonOperating | 1.14M | 1.74M | ||
| InterestIncomeNonOperating | 4.13M | 3.18M | 2.23M | 1.97M |
| OperatingIncome | -49.15M | -43.61M | -37.55M | -47.49M |
| OperatingExpense | 49.15M | 43.61M | 37.55M | 47.49M |
| ResearchAndDevelopment | 31.70M | 24.99M | 16.81M | 21.09M |
| SellingGeneralAndAdministration | 17.45M | 18.62M | 20.74M | 26.40M |
| GeneralAndAdministrativeExpense | 17.45M | 18.62M | 20.74M | 26.40M |
| OtherGandA | 17.45M | 18.62M | 20.74M | 26.40M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 35.04M | 11.36M | 11.27M | 11.24M |
| ShareIssued | 35.04M | 11.36M | 11.27M | 11.24M |
| TotalDebt | 4.48M | 5.47M | 6.38M | 7.24M |
| TangibleBookValue | 163.89M | 65.66M | 102.00M | 132.40M |
| InvestedCapital | 167.13M | 68.32M | 102.08M | 161.91M |
| WorkingCapital | 161.19M | 62.56M | 80.41M | 88.81M |
| NetTangibleAssets | 163.89M | 65.66M | 102.00M | 132.40M |
| CapitalLeaseObligations | 4.48M | 5.47M | 6.38M | 7.24M |
| CommonStockEquity | 167.13M | 68.32M | 102.08M | 161.91M |
| TotalCapitalization | 167.13M | 68.32M | 102.08M | 161.91M |
| TotalEquityGrossMinorityInterest | 167.13M | 68.32M | 102.08M | 161.91M |
| StockholdersEquity | 167.13M | 68.32M | 102.08M | 161.91M |
| GainsLossesNotAffectingRetainedEarnings | 2.00K | -31.00K | -688.00K | -211.00K |
| OtherEquityAdjustments | 2.00K | -31.00K | -688.00K | -211.00K |
| RetainedEarnings | -244.98M | -200.38M | -159.96M | -94.01M |
| AdditionalPaidInCapital | 412.08M | 268.73M | 262.72M | 256.13M |
| CapitalStock | 35.00K | 11.00K | 11.00K | 11.00K |
| CommonStock | 35.00K | 11.00K | 11.00K | 11.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 14.32M | 10.63M | 11.21M | 10.68M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.36M | 4.48M | 5.47M | 6.38M |
| LongTermDebtAndCapitalLeaseObligation | 3.36M | 4.48M | 5.47M | 6.38M |
| LongTermCapitalLeaseObligation | 3.36M | 4.48M | 5.47M | 6.38M |
| CurrentLiabilities | 10.96M | 6.15M | 5.74M | 4.30M |
| CurrentDebtAndCapitalLeaseObligation | 1.12M | 983.00K | 917.00K | 855.00K |
| CurrentCapitalLeaseObligation | 1.12M | 983.00K | 917.00K | 855.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.53M | 2.11M | 2.54M | 1.80M |
| PayablesAndAccruedExpenses | 7.30M | 3.05M | 2.28M | 1.64M |
| CurrentAccruedExpenses | 2.88M | 620.00K | 694.00K | 688.00K |
| Payables | 4.43M | 2.43M | 1.59M | 954.00K |
| TotalTaxPayable | 41.00K | |||
| AccountsPayable | 4.43M | 2.43M | 1.59M | 954.00K |
| TotalAssets | 181.45M | 78.95M | 113.29M | 172.60M |
| TotalNonCurrentAssets | 9.30M | 10.25M | 27.14M | 79.48M |
| OtherNonCurrentAssets | 772.00K | 756.00K | 761.00K | 1.61M |
| NonCurrentPrepaidAssets | 0.00 | 272.00K | 544.00K | |
| InvestmentsAndAdvances | 0.00 | 17.89M | 39.47M | |
| InvestmentinFinancialAssets | 0.00 | 17.89M | 39.47M | |
| AvailableForSaleSecurities | 17.89M | 39.47M | ||
| GoodwillAndOtherIntangibleAssets | 3.25M | 2.66M | 84.00K | 29.52M |
| OtherIntangibleAssets | 3.25M | 2.66M | 84.00K | |
| Goodwill | 0.00 | 29.52M | ||
| NetPPE | 5.28M | 6.56M | 7.87M | 8.89M |
| AccumulatedDepreciation | -1.11M | -824.00K | -483.00K | -236.00K |
| GrossPPE | 6.39M | 7.38M | 8.35M | 9.13M |
| Leases | 553.00K | 553.00K | 553.00K | 224.00K |
| OtherProperties | 5.25M | 6.23M | 7.24M | 8.38M |
| MachineryFurnitureEquipment | 587.00K | 599.00K | 557.00K | 527.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 172.16M | 68.70M | 86.15M | 93.11M |
| OtherCurrentAssets | 2.00K | 37.00K | 127.00K | 34.00K |
| RestrictedCash | 0.00 | |||
| PrepaidAssets | 1.86M | 2.85M | 1.16M | 1.22M |
| Receivables | 0.00 | 242.00K | 486.00K | 634.00K |
| AccruedInterestReceivable | 0.00 | 242.00K | 486.00K | 634.00K |
| CashCashEquivalentsAndShortTermInvestments | 170.29M | 65.58M | 84.37M | 91.23M |
| OtherShortTermInvestments | 7.49M | 25.99M | 60.24M | 55.51M |
| CashAndCashEquivalents | 162.80M | 39.59M | 24.13M | 35.72M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -35.87M | -37.60M | -26.58M | -35.10M |
| RepurchaseOfCapitalStock | -91.00K | -90.00K | -228.00K | |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 136.01M | 0.00 | 0.00 | |
| CapitalExpenditure | -63.00K | -45.00K | -120.00K | -596.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 163.54M | 40.33M | 24.87M | 36.47M |
| BeginningCashPosition | 40.33M | 24.87M | 36.47M | 169.39M |
| ChangesInCash | 123.21M | 15.46M | -11.60M | -132.92M |
| FinancingCashFlow | 139.87M | -91.00K | -90.00K | -228.00K |
| CashFlowFromContinuingFinancingActivities | 139.87M | -91.00K | -90.00K | -228.00K |
| NetOtherFinancingCharges | -83.00K | -91.00K | ||
| ProceedsFromStockOptionExercised | 3.94M | 0.00 | 0.00 | |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 136.01M | 0.00 | -90.00K | -228.00K |
| CommonStockPayments | -91.00K | -90.00K | -228.00K | |
| CommonStockIssuance | 136.01M | 0.00 | 0.00 | |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | 0.00 | |||
| InvestingCashFlow | 19.16M | 53.11M | 14.95M | -98.19M |
| CashFlowFromContinuingInvestingActivities | 19.16M | 53.11M | 14.95M | -98.19M |
| NetInvestmentPurchaseAndSale | 19.22M | 53.15M | 15.07M | -97.60M |
| SaleOfInvestment | 48.60M | 65.34M | 58.62M | 27.15M |
| PurchaseOfInvestment | -29.38M | -12.19M | -43.55M | -124.75M |
| NetPPEPurchaseAndSale | -63.00K | -45.00K | -120.00K | -596.00K |
| PurchaseOfPPE | -63.00K | -45.00K | -120.00K | -596.00K |
| OperatingCashFlow | -35.81M | -37.56M | -26.46M | -34.50M |
| CashFlowFromContinuingOperatingActivities | -35.81M | -37.56M | -26.46M | -34.50M |
| ChangeInWorkingCapital | 4.01M | -4.14M | 539.00K | -516.00K |
| ChangeInOtherCurrentLiabilities | -984.00K | -917.00K | -1.33M | -1.01M |
| ChangeInOtherCurrentAssets | -328.00K | -2.30M | 222.00K | 295.00K |
| ChangeInPayablesAndAccruedExpense | 4.06M | 343.00K | 1.38M | 616.00K |
| ChangeInAccruedExpense | 2.68M | -505.00K | 748.00K | 576.00K |
| ChangeInPayable | 1.38M | 848.00K | 631.00K | 40.00K |
| ChangeInAccountPayable | 1.38M | 848.00K | 631.00K | 40.00K |
| ChangeInPrepaidAssets | 1.26M | -1.26M | 265.00K | -418.00K |
| OtherNonCashItems | 1.01M | 1.01M | 1.37M | 1.05M |
| StockBasedCompensation | 4.12M | 6.09M | 6.69M | 10.36M |
| AssetImpairmentCharge | 0.00 | 29.52M | 0.00 | |
| AmortizationOfSecurities | -685.00K | -444.00K | 1.14M | 1.74M |
| DepreciationAmortizationDepletion | 332.00K | 341.00K | 248.00K | 117.00K |
| DepreciationAndAmortization | 332.00K | 341.00K | 248.00K | 117.00K |
| Depreciation | 332.00K | 341.00K | 248.00K | 117.00K |
| NetIncomeFromContinuingOperations | -44.60M | -40.42M | -65.95M | -47.25M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TARA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|